Press release
Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose
Far reaching implications for ease of widescale distribution and administration anytime, anywhere Better candidate for protection against COVID-19 variants
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"\n\nFar reaching implications for ease of widescale distribution and administration anytime, anywhere \n\n\nBetter candidate for protection against COVID-19 variants due to triple antigen targeting\n\n\nOravax Medical Inc. established to accelerate vaccine’s path to market \n\n\nClinical trials expected to commence Q2 2021\n\n\n GURUGRAM, India--(BUSINESS WIRE)--\nPremas Biotech, a developer of novel biotherapeutic and vaccine candidates, announced today the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP).\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210319005359/en/\nAccelerating the vaccine’s path to market, Premas, Oramed and other shareholders, have formed Oravax Medical Inc. which has received exclusive licenses from Oramed and Premas to develop oral COVID-19 vaccines.\n\nAfter a single dose of the Oravax COVID-19 capsule, efficacy was evident through antibody production in a pilot animal study. Oravax’s vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA) which protects the respiratory and gastrointestinal tracts against infection.\n\nPremas’ protein-based VLP (Virus Like Particle) vaccine candidate creates triple protection against the SARS CoV-2 virus Spike, Membrane, and Envelope targets. The vaccine candidate is also safe, efficacious and well tolerated at normal to high doses, and generated high titres of neutralizing antibodies. The VLP is manufactured using Premas’ proprietary D-Crypt™ platform, which is highly scalable and can be manufactured on large scales.\n\nPremas Biotech Co-Founder and Managing Director Dr. Prabuddha Kundu commented, “An oral COVID-19 vaccine that harnesses and combines the true potential of the two platforms, Premas’ D-Crypt™ technology platform with Oramed’s world-leading oral protein delivery platform POD® is an excellent example of a true collaboration and can rapidly advance into late-stage clinical trials. Oramed’s experience and success in conducting Phase 2 and 3 oral protein trials positions our program very favorably in the race to find an effective oral COVID-19 vaccine that can ...